tirzepatide europe approval France becomes first EU country to reimburse anti-obesity drugs Tirzepatide Tops Semaglutide for Weight

The numbers speak clearly

Meta-analyses have further confirmed that dual GLP-1/GIP receptor agonists are more effective than single GLP-1RAs in reversing liver fibrosis and reducing hepatic fat accumulation, suggesting a dose-dependent and receptor-combinatorial effect on liver outcomes (48)

Erythropoietic Protoporphyria (EPP) Treatment: MT-I is FDA-approved as a treatment for EPP, demonstrating the ability to mitigate symptoms by increasing melanin in the skin, absorbing UV, and reducing skin damage and pain [5]

If you vomit soon after taking a dose, miss doses, cannot keep fluids down, or feel more unwell, contact the prescriber or pharmacist

By targeting both GIP and GLP-1 receptors , it delivers powerful improvements in blood sugar regulation , weight management , and overall metabolic health

Is there clinical evidence that staying on GLP-1 therapy prevents weight regain